1. Sanofi, despite the pandemic, sees early gains from CEO Hudson's strategy — Trump administration to require insurers to cover COVID-19 vaccine — Regeneron/Sanofi's Libtayo gets priority review in NSCLC — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Recent Posts

  1. anonymous

    COVID Face To Face Shut Down?

    How soon to everyone being back home across the US? and then more layoffs?

  2. cafead

    Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted...

    via One month after Regeneron and Sanofi posted impressive data from a phase 3 trial of their PD-1 inhibitor Libtayo in first-line non-small cell lung cancer (NSCLC), the FDA has shifted the drug into the fast lane—possibly offering the companies...

  3. cafead

    Sanofi to Evaluate THOR-707 with Merck's Checkpoint Inhibitor Keytruda

    via Sanofi is partnering with Merck to test its THOR-707 compound with Merck’s checkpoint inhibitor Keytruda (pembrolizumab) in solid tumors. THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid...

  4. cafead

    Chemocentryx takes a leap of faith with avacopan

    via The failure of Inflarx’s IFX-1 had already sown doubts about Chemocentryx’s similarly acting lead project, avacopan, in the skin disease hidradenitis suppurativa. Now it seems Chemocentryx is going to ignore a new red flag: despite the phase...

  5. cafead

    Trump administration to require insurers cover coronavirus vaccines

    via The Trump administration will require most private health plans to cover an approved coronavirus vaccine and its administration with no cost-sharing once the shot is recommended by a Centers for Disease Control and Prevention panel. article...

  6. cafead

    AstraZeneca's Fasenra spares asthma patients from steroid use in large trial

    via In a single-arm phase 3b trial, Fasenra helped 62% of nearly 600 patients with severe asthma to go on about their lives without oral corticosteroids, AstraZeneca said Thursday. More patients, or 81%, had their daily steroid dose reduced to...

  7. anonymous


    So true they do ask, and you may want an ethical response because you will be scrutinized

  8. + Show More
  1. General Discussion

    Discussion boards of general interest for those in the pharma, biotech, medical device, and related industries
  2. Pharma/Biotech Companies

    Anonymous discussion boards for pharmaceutical and biotech companies
  3. Regional/Metro Area Boards

    Discussion and job opportunities by region
  4. Lost Civilizations

    Anonymous discussion boards for pharma/medical companies that no longer exist due to acquisition or other factors
  5. Laboratory/Diagnostic Sales

    Anonymous discussion boards for lab sales/diagnostics companies
  6. Animal Health Sales

    Anonymous discussion boards for animal health companies
  7. Medical Equipment/Device Sales

    Anonymous discussion boards for medical equipment/device companies
  8. PBMs

    Anonymous discussion boards for PBMs
  9. Pharma/Healthcare Marketing Agencies

    Anonymous discussion boards for pharma/healthcare marketing agencies
  10. Dental Reps

    Anonymous discussion boards for dental health companies
  11. Managed Care Specialists

    Anonymous discussion boards for managed care specialists
  12. Pharma IT

    Anonymous discussion boards for pharma IT employees

Forum Statistics

Latest Member:
Scott Hicks